Not yet taking people in ChinaPhase 2
Adebrelimab with other cancer drugs around surgery for operable non-small cell lung cancer
Tests adebrelimab with other drugs in people with lung cancer that can be removed.
Key facts
- Who runs it
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Where
- Shanghai, ChinaSee the site
- Trial code
- Registry title
- The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 180 people, planned
- Started
- Aug 2026
- Expected to end
- Dec 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection
- Adebrelimab Injection combined with HRS-7058 Capsule
- Record updated
- 15 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer that can be removed by surgery. It tests adebelizumab with other anti-cancer drugs before and after surgery.
- Age
- 18 to 70 years
- Sex
- Men and women can join.
- Disease stage
- Non-small cell lung cancer, Stage II, IIIA, or select Stage IIIB, confirmed by tissue or cell tests, where surgery to remove all the tumour is planned.
- Earlier treatment
- People who already had whole-body anti-cancer treatment for non-small cell lung cancer cannot join.
- Biomarker or test result
- People with non-squamous cell carcinoma must be tested for the EGFR gene and the ALK gene and/or by immunohistochemistry. A tumour tissue sample must be provided.
Main reasons for not taking part
- Mixed small cell and non-small cell lung cancer
- Earlier whole-body anti-cancer treatment for non-small cell lung cancer
- Chest radiotherapy or ablation received or planned
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing
- At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can; The ECOG score was 0 or 1. 4. Patients with histopathologically or cytologically confirmed Stage II, IIIA, or select Stage IIIB (AJCC 9th edition) non-small cell lung cancer who are candidates for curative-intent R0 surgical resection; 5.Combined genetic requirements : non-squamous cell carcinoma subjects must undergo EGFR gene detection and ALK gene and or immunohistochemical detection; 6.Can provide tumor tissue specimens, which can be archived or freshly obtained specimens for biomarker detection; 7.According to the RECIST v1.1 standard, subjects must have measurable target lesions examined by CT or MRI. Tumor imaging evaluation was performed within 28 days before the first administration; 8.There is sufficient hematology and organ function, as defined by the results of laboratory tests, to be completed within 7 days prior to the first dose of treatment : 9.Women of childbearing age must have a serum pregnancy test within 7 days before the first administration, and the result is negative. Women of childbearing age and men whose partners are women of childbearing age must agree to use an efficient method of contraception from the date of signing the informed consent to at least 26 weeks ( female subjects ) or 14 weeks ( male subjects ) after the last administration
Who cannot take part
- Small cell lung cancer ( SCLC ) and NSCLC mixed tumors confirmed by histology or cytology contain non-NSCLC pathological types such as small cell components; 3.Have previously received systematic anti-tumor therapy for non-small cell lung cancer other than this study ( including clinical research drugs ) ; 4.Participants who had received or planned to receive local treatment such as chest radiotherapy or ablation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in China
- Shanghai Pulmonary HospitalShanghai, ChinaContact: Chang Chen (principal investigator)No longer taking part
About the trial
What the trial wants to find out
This study is an open-label, multicenter phase II clinical trial of adebelizumab combined with other anti-tumor therapies in patients with non-small cell lung cancer. The aim of this study was to evaluate the safety, tolerability and efficacy of adebelizumab combined with other anti-tumor therapies in patients with resectable non-small cell lung cancer ( NSCLC )
The 2 groups in the trial
- PART ATreatment being tested
Treatment: Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection
- PART BTreatment being tested
Treatment: Adebrelimab Injection combined with HRS-7058 Capsule
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase II Clinical Study of Adebelizumab Combined With Other Anti-tumor Treatments as a Perioperative Treatment for Resectable Non-small Cell Lung Cancer
- Plain-language title
- Adebrelimab with other cancer drugs around surgery for operable non-small cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07704645, who can take part
- Record updated
- 15 July 2026